However, due to the limitations of AChE inhibitors [73,74], including dosage constraints and inadequate long-term efficacy, BChE inhibitors are emerging as a new therapeutic target, suggesting that inhibiting BChE could be a potential therapeutic approach for cognitive impairments in SZ, BPD, and MDD. Here, BCHE is linked to major depressive disorder.